Based on the information available, there is a time limit on the Yervoy discount. The drug, which is a type of immunotherapy used to treat certain types of cancer, is manufactured by Bristol-Myers Squibb. According to DrugPatentWatch.com, the company's patent for Yervoy (ipilimumab) is set to expire in 2026 [1]. After the patent expires, it is likely that generic versions of the drug will become available, which could lead to a decrease in price.

Currently, Bristol-Myers Squibb offers a patient assistance program for Yervoy, which provides financial assistance to eligible patients who are prescribed the drug [2]. However, the program has certain eligibility requirements and may not be available to all patients. Additionally, the program is subject to change and may not be available indefinitely.

It is also worth noting that the cost of Yervoy can vary depending on a number of factors, including the dosage and the specific healthcare provider. Patients are encouraged to speak with their healthcare provider and insurance company to understand the specific costs and coverage options for Yervoy.

In summary, based on the available information, there is a time limit on the Yervoy discount as the patent for the drug is set to expire in 2026. Bristol-Myers Squibb currently offers a patient assistance program for the drug, but it has certain eligibility requirements and may not be available indefinitely. The cost of Yervoy can vary and patients are encouraged to speak with their healthcare provider and insurance company to understand the specific costs and coverage options.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/yervoy>
[2] <https://www.bms.com/patients/patient-assistance.html>